Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

High-Intensity Interval Training Is Feasible in Women at High Risk for Breast Cancer.

Coletta AM, Brewster AM, Chen M, Li Y, Bevers TB, Basen-Engquist K, Gilchrist SC.

Med Sci Sports Exerc. 2019 Nov;51(11):2193-2200. doi: 10.1249/MSS.0000000000002048.

PMID:
31269007
2.

Supplemental ultrasound screening in patients with a history of lobular neoplasia.

Phalak KA, Milton DR, Yang WT, Bevers TB, Dogan BE.

Breast J. 2019 Mar;25(2):250-256. doi: 10.1111/tbj.13191. Epub 2019 Jan 24.

PMID:
30675929
3.

Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position.

Helvie MA, Bevers TB.

J Natl Compr Canc Netw. 2018 Nov;16(11):1398-1404. doi: 10.6004/jnccn.2018.7081. Review.

PMID:
30442738
4.

Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R.

J Natl Compr Canc Netw. 2018 Nov;16(11):1362-1389. doi: 10.6004/jnccn.2018.0083.

PMID:
30442736
5.

Randomized trial of a patient-centered decision aid for promoting informed decisions about lung cancer screening: Implementation of a PCORI study protocol and lessons learned.

Lowenstein LM, Escoto KH, Leal VB, Bailey L, Bevers TB, Cantor SB, Cinciripini PM, Jacobs LE, Esparza A, Godoy MC, Housten AJ, Lin H, Luckett P, Munden RF, Rabius V, Volk RJ.

Contemp Clin Trials. 2018 Sep;72:26-34. doi: 10.1016/j.cct.2018.07.007. Epub 2018 Jul 20.

6.

Resistance to discontinuing breast cancer screening in older women: A qualitative study.

Housten AJ, Pappadis MR, Krishnan S, Weller SC, Giordano SH, Bevers TB, Volk RJ, Hoover DS.

Psychooncology. 2018 Jun;27(6):1635-1641. doi: 10.1002/pon.4708. Epub 2018 Apr 17.

7.

Preferences for Communicating about Breast Cancer Screening Among Racially/Ethnically Diverse Older Women.

Hoover DS, Pappadis MR, Housten AJ, Krishnan S, Weller SC, Giordano SH, Bevers TB, Goodwin JS, Volk RJ.

Health Commun. 2019 Jun;34(7):702-706. doi: 10.1080/10410236.2018.1431026. Epub 2018 Jan 26.

PMID:
29373069
8.

Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.

Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC.

Fam Cancer. 2018 Apr;17(2):287-294. doi: 10.1007/s10689-017-0034-6.

PMID:
28988289
9.

NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.

Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ.

Cancer Prev Res (Phila). 2017 Nov;10(11):625-634. doi: 10.1158/1940-6207.CAPR-17-0076. Epub 2017 Oct 4.

10.

Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.

Blakeslee SB, McCaskill-Stevens W, Parker PA, Gunn CM, Bandos H, Bevers TB, Battaglia TA, Fagerlin A, Müller-Nordhorn J, Holmberg C.

Patient Educ Couns. 2017 Dec;100(12):2346-2354. doi: 10.1016/j.pec.2017.06.033. Epub 2017 Jun 27.

11.

Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.

Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL Jr, Sneige N, Gong Y, Bevers TB.

Cancer Cytopathol. 2017 Aug;125(8):644-651. doi: 10.1002/cncy.21877. Epub 2017 May 12.

12.

Mammographic breast density is associated with the development of contralateral breast cancer.

Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M Jr, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH.

Cancer. 2017 Jun 1;123(11):1935-1940. doi: 10.1002/cncr.30573. Epub 2017 Jan 30.

13.

A brief measure of Smokers' knowledge of lung cancer screening with low-dose computed tomography.

Lowenstein LM, Richards VF, Leal VB, Housten AJ, Bevers TB, Cantor SB, Cinciripini PM, Cofta-Woerpel LM, Escoto KH, Godoy MC, Linder SK, Munden RF, Volk RJ.

Prev Med Rep. 2016 Jul 26;4:351-6. doi: 10.1016/j.pmedr.2016.07.008. eCollection 2016 Dec.

14.

Clinical Breast Examination and Breast Cancer Screening Guideline.

Anderson BO, Bevers TB, Carlson RW.

JAMA. 2016 Apr 5;315(13):1403-4. doi: 10.1001/jama.2016.0686. No abstract available.

PMID:
27046372
15.

Epidemiological risk factors associated with inflammatory breast cancer subtypes.

Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM.

Cancer Causes Control. 2016 Mar;27(3):359-66. doi: 10.1007/s10552-015-0712-3. Epub 2016 Jan 21.

16.

User Perceptions and Reactions to an Online Cancer Risk Assessment Tool: a Process Evaluation of Cancer Risk Check.

Hovick SR, Bevers TB, Vidrine JI, Kim S, Dailey PM, Jones LA, Peterson SK.

J Cancer Educ. 2017 Mar;32(1):141-147. doi: 10.1007/s13187-015-0939-4.

17.

Chemoprevention for Breast Cancer.

Pruthi S, Heisey RE, Bevers TB.

Ann Surg Oncol. 2015 Oct;22(10):3230-5. doi: 10.1245/s10434-015-4715-9. Epub 2015 Jul 23.

18.

Breast Cancer Risk Reduction, Version 2.2015.

Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.

J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.

PMID:
26150582
19.

Breast cancer risk reduction therapy: the low-hanging fruit.

Bevers TB.

J Natl Compr Canc Netw. 2015 Apr;13(4):376-8. No abstract available.

PMID:
25870373
20.

Should CMS cover lung cancer screening for the fully informed patient?

Volk RJ, Hawk E, Bevers TB.

JAMA. 2014 Sep 24;312(12):1193-4. doi: 10.1001/jama.2014.12709. No abstract available.

21.

Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer.

Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL.

J Hum Nutr Diet. 2015 Jun;28(3):272-82. doi: 10.1111/jhn.12229. Epub 2014 Mar 19.

22.

Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting.

Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, Bevers TB.

Cancer Med. 2014 Jun;3(3):492-9. doi: 10.1002/cam4.223. Epub 2014 Mar 18.

23.

Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography.

Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB.

Prev Med. 2014 May;62:60-3. doi: 10.1016/j.ypmed.2014.02.006. Epub 2014 Feb 8.

24.

An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis.

Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM.

Biomark Cancer. 2013 Nov 19;5:71-80. doi: 10.4137/BIC.S13236. eCollection 2013.

25.

Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision.

Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL Jr, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L.

Clin Breast Cancer. 2013 Dec;13(6):439-49. doi: 10.1016/j.clbc.2013.08.007. Epub 2013 Oct 8.

26.

Brain responses to erotic and other emotional stimuli in breast cancer survivors with and without distress about low sexual desire: a preliminary fMRI study.

Versace F, Engelmann JM, Jackson EF, Slapin A, Cortese KM, Bevers TB, Schover LR.

Brain Imaging Behav. 2013 Dec;7(4):533-42. doi: 10.1007/s11682-013-9252-1.

27.

The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results.

Guo M, Gong Y, Wang J, Dawlett M, Patel S, Liu P, Bevers TB, Sneige N.

Cancer Cytopathol. 2013 Feb;121(2):79-85. doi: 10.1002/cncy.21240. Epub 2012 Dec 5.

28.

Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.

Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL.

Cancer Prev Res (Phila). 2012 Sep;5(9):1144-54. doi: 10.1158/1940-6207.CAPR-12-0117. Epub 2012 Jul 24.

29.

Exemestane in the prevention setting.

Litton JK, Bevers TB, Arun BK.

Ther Adv Med Oncol. 2012 May;4(3):107-12. doi: 10.1177/1758834012438214.

30.

Breast cancer prevention: an update of the STAR trial.

Bevers TB.

Curr Treat Options Oncol. 2010 Dec;11(3-4):66-9. doi: 10.1007/s11864-010-0124-2. No abstract available.

PMID:
21061192
31.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH.

J Natl Compr Canc Netw. 2010 Oct;8(10):1112-46. No abstract available.

PMID:
20971838
32.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

33.

Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition.

Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM.

J Womens Health (Larchmt). 2010 Mar;19(3):371-9. doi: 10.1089/jwh.2009.1605.

34.

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Nov;7(10):1060-96. Review. No abstract available. Erratum in: J Natl Compr Canc Netw. 2010 Feb;8(2):xxxvii. Buys, Sandra [corrected to Buys, Saundra]; Yaneeklov, Thomas [corrected to Yankeelov, Thomas].

PMID:
19930975
35.

Breast awareness: a shift in the paradigm of breast self-examination.

Bevers TB.

J Natl Compr Canc Netw. 2009 Nov;7(10):1042-3. No abstract available.

PMID:
19930973
36.

Alcohol and cancer incidence in women.

Bevers TB.

Curr Oncol Rep. 2009 Nov;11(6):417-20. No abstract available.

PMID:
19840518
37.

Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.

Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, Shumaker SA.

J Clin Oncol. 2009 Nov 1;27(31):5144-52. doi: 10.1200/JCO.2008.21.0716. Epub 2009 Sep 21.

38.

Ultrasound for the screening of breast cancer.

Bevers TB.

Curr Oncol Rep. 2008 Nov;10(6):527-8. No abstract available.

PMID:
18928668
39.

Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience.

Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1096-103. doi: 10.1158/1055-9965.EPI-08-0201.

40.

CT screening for lung cancer.

Bevers TB.

Curr Oncol Rep. 2007 Nov;9(6):501-2. No abstract available.

PMID:
17991359
41.
42.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Sep;5(8):676-701. No abstract available.

PMID:
17927926
43.

A human papillomavirus testing system in women with abnormal Pap results: a comparison study with follow-up biopsies.

Guo M, Patel SJ, Chovanec M, Jan YJ, Tarco E, Bevers TB, Anderson K, Sneige N.

Acta Cytol. 2007 Sep-Oct;51(5):749-54.

PMID:
17910345
44.

Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged <or=55 years.

Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, Wang LE.

Breast Cancer Res Treat. 2008 Jul;110(2):357-66. Epub 2007 Sep 13.

45.

Raloxifene and the prevention of breast cancer.

Bevers TB.

Expert Opin Pharmacother. 2006 Nov;7(16):2301-7. Review.

PMID:
17059385
46.

Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?

Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB.

Breast Cancer Res Treat. 2007 May;102(3):347-56. Epub 2006 Sep 21.

PMID:
17028980
47.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
48.

Breast cancer screening and diagnosis.

Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 May;4(5):480-508. No abstract available.

PMID:
16687096
49.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
50.

Quality of life and sexual functioning in cervical cancer survivors.

Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC.

J Clin Oncol. 2005 Oct 20;23(30):7428-36.

PMID:
16234510

Supplemental Content

Loading ...
Support Center